Neurology: Volume 89, Number 9, August 29, 2017 Exam #1 - Prognostic relevance of MOG antibodies in children with an acquired demyelinating syndrome

About this course

  • Released: 08/29/2017
  • Expires: 08/29/2020


PROGNOSTIC RELEVANCE OF MOG ANTIBODIES IN CHILDREN WITH AN ACQUIRED DEMYELINATING SYNDROME

LEARNING OBJECTIVES:

Upon completion of the article by Hennes et al, the participant should be able to:

  • Identify clinical features in this study seen in conjunction with high anti-myelin oligodendrocyte glycoprotein (MOG) antibodies in a cohort of children with acquired demyelinating syndromes
  • Describe the prognostic role for anti-MOG antibodies in identifying children after an initial demyelinating event who are at high risk of subsequent development of multiple sclerosis (MS) in this study
  • Discuss the sensitivity and specificity of anti-MOG antibodies in the diagnosis of non-MS disease courses following an initial demyelinating event observed in this study


CORE COMPETENCIES:

The article by Hennes et al covers the following core competency:

  • Medical Knowledge
     

AUTHOR DISCLOSURES:

Refer to Information and Author section available in the Tool Bar for each article.
 

THIS PAGE IS REQUIRED READING BEFORE BEGINNING ALL ACCME-ACCREDITED COURSES

ACCREDITATION STATEMENT

The American Academy of Neurology Institute is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

MISSION STATEMENT/PROGRAM OBJECTIVES

After evaluating a specific article published in Neurology, participants in the CME activity should be able to demonstrate an increase in, or affirmation of, their knowledge of clinical medicine. Participants should be able to evaluate the appropriateness of the clinical information as it applies to the provision of patient care.

PARTICIPANTS

This program is designed for physicians who are involved in providing patient care and who wish to advance their current knowledge of clinical medicine.

AMA CREDIT DESIGNATION STATEMENT

The American Academy of Neurology Institute designates this journal-based-CME activity for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

DISCLOSURES

James WM Owens Jr. MD, PhD receives royalties from UpToDate, Waltham, MA; grant support from NIH (PI, K08NS054882); and a stipend in his editorial capacity for Neurology. Adam Kelly, MD, has served as a guest editor of Continuum (April 2014) and receives a stipend in his editorial capacity for Neurology.

COMMERCIAL SUPPORT

This CME program receives no commercial support.

ACCME